Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin alphaIIbbeta3 with antiplatelet and antithrombotic activity that blocks the platelet alphaIIbbeta3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
Reinheit:
97.10%
CAS Nummer:
[339086-80-5]
Target-Kategorie:
Integrin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten